Medindia

X

Trius' Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting

Thursday, September 17, 2009 General News J E 4
Advertisement
SAN DIEGO, Sept. 12 Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA. Additional data from a previously announced Phase 2 study of torezolid (TR-701) reiterate the high efficacy of torezolid at the low 200 mg dose against methicillin-sensitive and methicillin-resistant bacteria in patients with severe complicated skin and skin structure infections (cSSSI). In vitro studies presented at ICAAC highlight the potency of torezolid against linezolid-resistant MRSA and cfr-mediated resistant bacteria.

"The package of data Trius is presenting at ICAAC provides compelling evidence of the high efficacy of torezolid against difficult to treat bacterial skin infections, including potency against bacterial strains proven to be resistant to linezolid," said Philippe Prokocimer, M.D., chief medical officer at Trius." There is an urgent need for more potent antibiotics like torezolid with different mechanisms of action that can circumvent drug resistance pathways."

ICAAC data presentations are as follows:

Saturday, September 12

(Poster Session 024, 11:30 am - 1:30 pm)

(Poster Session 004, 11:30 am - 1:30 pm)

Sunday, September 13

(Poster Session 082a, 11:15 am - 1:15 pm)

Monday, September 14

(Poster Session 155, 11:15 am - 1:15 pm)

Tuesday, September 15

(Poster Session 226, 9:00 am - 11:00 am)

Copies of these posters will be available on the Trius Web site following the ICAAC meeting.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant, gram-positive bacterial pathogens including those resistant to linezolid, the only currently marketed antibacterial drug of the oxazolidinone class. Trius' pipeline includes two preclinical programs with lead candidates for serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.

-- L1-335/355: Safety and Efficacy of TR-701 in a Phase 2 Randomized, Double-Blind Study in Patients with Severe Complicated Skin and Skin Structure Infections (cSSSI)

SOURCE Trius Therapeutics, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
GENova issues clarifying press release
S
Tosho's Satisfaction With Health Robotics Steers t...